Search Results
Feb 02, 2026, 11:07 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS),
More news about: Piramal Pharma Solutions
Feb 02, 2026, 11:00 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS),
More news about: Piramal Pharma Solutions
Jan 31, 2026, 07:57 ET Piramal Pharma Limited annuncia i risultati del terzo trimestre e dei primi nove mesi dell'anno fiscale 2026
salute. Inoltre, una delle società collegate di PPL, Abbvie Therapeutics India Private Limited, una joint venture tra Abbvie e PPL, è emersa come uno dei leader di mercato nel settore della terapia oftalmologica nel mercato farmaceutico indiano. Inoltre, PPL detiene una partecipazione strategica di minoranza
More news about: Piramal Pharma Limited
Jan 30, 2026, 07:33 ET PPL Corporation to Conduct Webcast on 2025 Earnings Results
www.pplweb.com/investors for 90 days after the call.About PPL PPL Corporation (NYSE: PPL), headquartered in Allentown, Pennsylvania, is a leading U.S. energy company focused on providing electricity and natural gas safely,
More news about: PPL Services Corporation
Jan 30, 2026, 03:07 ET Piramal Pharma Limited gibt Ergebnisse für das dritte Quartal und die ersten neun Monate des Geschäftsjahres 2026 bekannt
Limited:Piramal Pharma Limited (PPL), (NSE: PPLPHARMA) (BSE: 543635), bietet über seine 171 globalen Entwicklungs- und Produktionsstätten und ein weltweites Vertriebsnetz in über 100 Ländern ein Portfolio an differenzierten Produkten und Dienstleistungen an. PPL umfasst Piramal Pharma Solutions
More news about: Piramal Pharma Limited
Jan 29, 2026, 13:24 ET Piramal Pharma Limited anuncia resultados del tercer trimestre y nueve meses del año fiscal 2026
Además, una de las empresas asociadas de PPL, Abbvie Therapeutics India Private Limited, una empresa conjunta entre Abbvie y PPL, se ha consolidado como uno de los líderes del mercado en el área de terapia oftalmológica en el mercado farmacéutico indio. Asimismo, PPL cuenta con una inversión minoritaria
More news about: Piramal Pharma Limited
Jan 29, 2026, 13:17 ET Piramal Pharma Limited annonce ses résultats pour le troisième trimestre et les neuf premiers mois de l'exercice 2026
Limited :Piramal Pharma Limited (PPL), (NSE : PPLPHARMA) (BSE : 543635) propose un portefeuille de produits et de services différenciés grâce à ses 171 sites de développement et de fabrication dans le monde et à un réseau de distribution mondial s'étendant à plus de 100 pays. PPL comprend Piramal Pharma
More news about: Piramal Pharma Limited
Jan 29, 2026, 09:00 ET Pasadena Private Lending and Eagle Point Credit Management Announce $105 Million Strategic Capital Partnership
Lending, Inc. ("PPL"), a leading private credit provider to lower middle-market businesses, and Eagle Point Credit Management LLC ("Eagle Point"), an innovative private credit investment manager, are pleased to announce that Eagle Point has become a strategic partner across the PPL capital structure,
More news about: Pasadena Private Financial Group
Jan 29, 2026, 00:46 ET Piramal Pharma Limited Announces Results for Q3 and 9M FY26
Limited:Piramal Pharma Limited (PPL), (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions
More news about: Piramal Pharma Limited
Jan 29, 2026, 00:35 ET Piramal Pharma Limited Announces Results for Q3 and 9M FY26
Limited:Piramal Pharma Limited (PPL), (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions
More news about: Piramal Pharma Limited
Jan 20, 2026, 08:00 ET PPL Corporation statement on Trump-Shapiro call for new power auction to spur construction of power plants paid for by data centers
reliable and affordable energy future for our customers ─ all while enabling the U.S. to win the AI race."About PPLPPL Corporation (NYSE: PPL), headquartered in Allentown, Pennsylvania, is a leading U.S. energy company focused on providing electricity and natural
More news about: PPL Services Corporation
Jan 14, 2026, 09:00 ET Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
the animal health ecosystem, including VETmAb Biosciences in canine biologics, Dalan Animal Health in shrimp vaccines for sustainable aquaculture, DOG PPL, a community and wellness platform centered around dog parks."The animal health sector is emerging as a major global growth area, driven by advances
More news about: Yuyu Pharma
Jan 13, 2026, 14:38 ET Edward Rogers Invests in the Toronto Polar Bears, Part of the Pro Padel League
Pro Padel League's (PPL) and is the only Canadian franchise. Mr. Rogers is the Executive Chair of Rogers Communications, and is Chair of Rogers Bank, the Toronto Blue Jays,
More news about: Toronto Polar Bears
Jan 13, 2026, 09:00 ET Pasadena Private Lending Exceeds $116 Million in New Originations in 2025, Surpasses $386 Million in Total Loans
customary borrower paydowns and payoffs—PPL grew to more than $182 million in outstanding loans, supporting over 42 active borrowers across 24 industries and more than 15 states.Now in its seventh full year of operations, PPL has originated more than $386 million
More news about: Pasadena Private Financial Group
Jan 13, 2026, 08:54 ET Premier Plus Lending Welcomes Mike Pandazos as Director of Strategic Growth
LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Premier Plus Lending (PPL) today announced the appointment of Mike Pandazos as Director of Strategic Growth, a newly established leadership role supporting the company's continued
More news about: Premier Plus Lending
Jan 10, 2026, 13:43 ET Piramal Pharma ottiene un notevole aumento del punteggio nella valutazione della sostenibilità aziendale (CSA) a livello globale condotta da S&P nel 2025
Inoltre una delle società associate di PPL, Abbvie Therapeutics India Private Limited – una joint venture tra Abbvie e PPL – si è affermata come una delle imprese principali nel settore farmaceutico indiano, specificamente nell'area della terapia oftalmologica. PPL inoltre detiene una partecipazione strategica
More news about: Piramal Pharma Limited
Jan 10, 2026, 13:40 ET Piramal Pharma erzielt deutliche Punktzahlsteigerung bei der Bewertung der Unternehmensnachhaltigkeit (CSA) von S&P Global für 2025
beiträgt." PPL nutzt die Dynamik und die Erkenntnisse aus dem CSA, um seine Nachhaltigkeitsbemühungen weiter zu verstärken und seine Partner weiterhin dabei zu unterstützen, positive Veränderungen voranzutreiben. Informationen zu Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE:
More news about: Piramal Pharma Limited
Jan 10, 2026, 06:14 ET Piramal Pharma obtient une augmentation notable de son score lors de l'évaluation mondiale de la durabilité des entreprises (CSA) de 2025 de S&P
l'un des cadres de référence les plus respectés en matière de développement durable au niveau international.Piramal Pharma Limited (PPL), qui englobe, entre autres, Piramal Pharma Solutions - une organisation de développement et de fabrication sous contrat (CDMO) de premier plan au niveau
More news about: Piramal Pharma Limited
Jan 10, 2026, 06:11 ET Piramal Pharma logra un notable aumento de puntuación en la Evaluación S&P CSA 2025
Además, una de las empresas asociadas de PPL, AbbVie Therapeutics India Private Limited, una empresa conjunta entre AbbVie y PPL, se ha consolidado como uno de los líderes del mercado en el área de terapia oftalmológica en el mercado farmacéutico indio. Asimismo, PPL tiene una inversión minoritaria estratégica
More news about: Piramal Pharma Limited
Jan 09, 2026, 15:49 ET Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Leveraging the momentum and insights gained from the CSA, PPL is poised to further enhance its sustainability efforts and continue helping its partners drive positive change. About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of
More news about: Piramal Pharma Limited
Jan 09, 2026, 15:43 ET Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Leveraging the momentum and insights gained from the CSA, PPL is poised to further enhance its sustainability efforts and continue helping its partners drive positive change. About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of
More news about: Piramal Pharma Limited
Jan 06, 2026, 08:57 ET Premier Plus Lending Expands Footprint with New Palm Desert Headquarters Following Strongest Year on Record
LOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- Premier Plus Lending (PPL), one of California's fastest-growing mortgage companies, announced today that it has officially purchased a 7,500+ square-foot commercial building on El
More news about: Premier Plus Lending
Dec 16, 2025, 08:39 ET Premier Plus Lending Welcomes Chandler Robbins as Senior Mortgage Advisor
ANGELES, Dec. 16, 2025 /PRNewswire/ -- Premier Plus Lending (PPL) is pleased to announce the addition of Chandler Robbins as its newest Senior Mortgage Advisor. Robbins joins PPL at a point of great momentum and will be integral in supporting the firm's expanding footprint
More news about: Premier Plus Lending
Dec 15, 2025, 17:51 ET Piramal Pharma Solutions dimostra il suo impegno verso l'eccellenza con un eccezionale Net Promoter Score
Inoltre una delle società associate di PPL, AbbVie Therapeutics India Private Limited – una joint venture tra AbbVie e PPL – si è affermata come una delle imprese principali nel settore farmaceutico indiano, specificamente nell'ambito della terapia oftalmologica. PPL inoltre detiene una partecipazione strategica
More news about: Piramal Pharma Solutions
Dec 15, 2025, 17:46 ET Piramal Pharma Solutions demonstriert Engagement für Spitzenleistungen mit hervorragendem Net Promoter Score
eines der verbundenen Unternehmen von PPL, AbbVie Therapeutics India Private Limited, ein Joint Venture zwischen AbbVie und PPL, zu einem der Marktführer im Bereich der ophthalmologischen Therapien auf dem indischen Pharmamarkt entwickelt. Des Weiteren hält PPL eine strategische Minderheitsbeteiligung
More news about: Piramal Pharma Solutions